Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.

摘要

A multicentre randomised trial of 424 patients demonstrated a 12% survival benefit with the addition of cetuximab to radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN) [1]. Radiotherapy was delivered using conventional fractionation (70 Gy using 2.0 Gy/daily fraction over 46 days), hyperfractionation (72.0-76.8 Gy using 1.2 Gy/twice daily fraction over 39-43 days) or a concomitant boost regimen (72 Gy over 39 days). The median age was 56 years (range 34-81 years) in the cetuximab with radiotherapy group. Grades 3-5 radiation dermatitis and mucositis were reported in 23% and 56%, respectively, in the radiotherapy with cetuximab group.